Key result
Cardiac neuronal nitric oxide synthase (nNOS) is upregulated in hypertension and protects the heart from adverse remodeling via positive lusitropy and cGMP/PKG-dependent phosphorylation.
This review elucidates the protective role and regulatory mechanisms of neuronal nitric oxide synthase (nNOS) in the hypertensive myocardium, highlighting its potential as a therapeutic target for hypertensive cardiomyopathy.
Answers are grounded in this paper and cite their sources.
nNOS may emerge as a therapeutic target in hypertensive cardiomyopathy; leaves open clinical translation pending prospective trials.
Hypertension is a prevalent condition worldwide and is the key risk factor for fatal cardiovascular complications, such as stroke, sudden cardiac death and heart failure. Reduced bioavailability of nitric oxide (NO) in the endothelium is an important precursor for impaired vasodilation and hypertension. In the heart, NO deficiency deteriorates the adverse consequences of pressure-overload and causes cardiac hypertrophy, fibrosis and myocardial infarction which lead to fatal heart failure and sudden cardiac death. Recent consensus is that both endothelial and neuronal nitric oxide synthases (eNOS or NOS3 and nNOS or NOS1) are the constitutive sources of NO in the myocardium. Between the two, nNOS is the predominant isoform of NOS that controls intracellular Ca2+ homeostasis, myocyte contraction, relaxation and signaling pathways including nitroso-redox balance. Notably, our recent research indicates that cardiac eNOS protein is reduced but nNOS protein expression and activity are increased in hypertension. Furthermore, nNOS is induced by the interplay between angiotensin II (Ang II) type 1 receptor (AT1R) and Ang II type 2 receptor (AT2R), mediated by NADPH oxidase and reactive oxygen species (ROS)-dependent eNOS activity in cardiac myocytes. nNOS, in turn, protects the heart from pathogenesis via positive lusitropy in hypertension. Soluble guanylate cyclase (sGC)-cGMP/PKG-dependent phosphorylation of myofilament proteins are novel targets of nNOS in hypertensive myocardium. In this short review, we will endeavor to overview new findings of the up-stream and downstream regulation of cardiac nNOS in hypertension, shed light on the underlying mechanisms which may be of therapeutic value in hypertensive cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Yin Hua Zhang (2016) conducted a review in Hypertension. Neuronal nitric oxide synthase (nNOS) was evaluated. Cardiac neuronal nitric oxide synthase (nNOS) is upregulated in hypertension and protects the heart from adverse remodeling via positive lusitropy and cGMP/PKG-dependent phosphorylation.
Synapse has enriched 10 related papers. Consider them for comparative context: